328 Preclinical analyses and proof of concept clinical study of Epstein Barr Virus (EBV) specific genetically modified T cells against EBV associated malignancies
Xinfeng Chen(Henan Cancer Hospital), Yi Zhang(Tianjin Medical University General Hospital), Xudong Zhang(First Affiliated Hospital of Zhengzhou University), Dan Wang(ARTS Group (China)), Xi Zhang(Army Medical University), Deping Han(Shanghai CASB Biotechnology (China)), Ling Li(First Affiliated Hospital of Zhengzhou University), Mingzhi Zhang(First Affiliated Hospital of Zhengzhou University), Renata Stripecke(University of Cologne), Jianmin Huan(First Affiliated Hospital of Zhengzhou University), Scott R. Burrows(Australian National University)
Cited by 0
Related Papers
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
|The Lancet|2020|29.1k
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
|New England Journal of Medicine|2020|5.5k
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
|Cellular Physiology and Biochemistry|2017|4.1k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Roles of IFN-γ in tumor progression and regression: a review
|Biomarker Research|2020|1.2k